SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype

Journal of Leukocyte Biology

Volumn 99, Issue 5, 2016, Pages 711-721

  Lombardi, Maria Stella ^c   Gilliéron, Corine ^c   Dietrich, Damien ^c   Gabay, Cem ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c NONE

Author keywords

Dendritic cells; Inflammation; Macrophages; Monocytes

Indexed keywords

ARN 3236; CREB REGULATED TRANSCRIPTION COACTIVATOR 3; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENZYME INHIBITOR; HG 9 91 01; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHOSPHOTRANSFERASE; PROTEIN KINASE LKB1; SALT INDUCIBLE KINASE 1; SALT INDUCIBLE KINASE 2; SALT INDUCIBLE KINASE 3; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; CARBANILAMIDE DERIVATIVE; CRTC3 PROTEIN, HUMAN; GAMMA INTERFERON; HDAC4 PROTEIN, HUMAN; HG-9-91-01; HISTONE DEACETYLASE; IL10 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; PROTEIN SERINE THREONINE KINASE; PYRIMIDINE DERIVATIVE; REPRESSOR PROTEIN; SMALL INTERFERING RNA; STK11 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; AGONISTS; ANTAGONISTS AND INHIBITORS; CELL POLARITY; DRUG EFFECTS; ENZYMOLOGY; GENE SILENCING; METABOLISM; MONOCYTE; PATHOLOGY; PHOSPHORYLATION;

CELL POLARITY; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MACROPHAGES; MONOCYTES; MYELOID CELLS; PHENOTYPE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; RECEPTORS, INTERLEUKIN-1; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84964758573     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.2A0715-307R     Document Type: Article

References (45)

1. Mylonas, K. J., Nair, M. G., Prieto-Lafuente, L., Paape, D., Allen, J. E. (2009) Alternatively activated macrophages elicited by helminth infection can be reprogrammed to enable microbial killing. J. Immunol. 182, 3084-3094.
2. Duluc, D., Corvaisier, M., Blanchard, S., Catala, L., Descamps, P., Gamelin, E., Ponsoda, S., Delneste, Y., Hebbar, M., Jeannin, P. (2009) Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int. J. Cancer 125, 367-373.
3. Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., Colombo, M. P. (2005) Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65, 3437-3446.
4. Porcheray, F., Viaud, S., Rimaniol, A. C., Léone, C., Samah, B., Dereuddre-Bosquet, N., Dormont, D., Gras, G. (2005) Macrophage activation switching: an asset for the resolution of inflammation. Clin. Exp. Immunol. 142, 481-489.
5. Sica, A., Mantovani, A. (2012) Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787-795.
6. Martinez, F. O., Gordon, S. (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6, 13.
7. Xue, J., Schmidt, S. V., Sander, J., Draffehn, A., Krebs, W., Quester, I., De Nardo, D., Gohel, T. D., Emde, M., Schmidleithner, L., Ganesan, H., Nino-Castro, A., Mallmann, M. R., Labzin, L., Theis, H., Kraut, M., Beyer, M., Latz, E., Freeman, T. C., Ulas, T., Schultze, J. L. (2014) Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40, 274-288.
8. Serhan, C. N., Savill, J. (2005) Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6, 1191-1197.
9. Lawrence, T., Gilroy, D. W. (2007) Chronic inflammation: a failure of resolution? Int. J. Exp. Pathol. 88, 85-94.
10. Fleming, B. D., Mosser, D. M. (2011) Regulatory macrophages: setting the threshold for therapy. Eur. J. Immunol. 41, 2498-2502.
11. Mikita, J., Dubourdieu-Cassagno, N., Deloire, M. S., Vekris, A., Biran, M., Raffard, G., Brochet, B., Canron, M. H., Franconi, J. M., Boiziau, C., Petry, K. G. (2011) Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult. Scler. 17, 2-15.
12. Gerber, J. S., Mosser, D. M. (2001) Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. J. Immunol. 166, 6861-6868.
13. Asadullah, K., Sterry, W., Volk, H. D. (2003) Interleukin-10 therapy—review of a new approach. Pharmacol. Rev. 55, 241-269.
14. O’Garra, A., Barrat, F. J., Castro, A. G., Vicari, A., Hawrylowicz, C. (2008) Strategies for use of IL-10 or its antagonists in human disease. Immunol. Rev. 223, 114-131.
15. Huizinga, T. W., Keijsers, V., Yanni, G., Hall, M., Ramage, W., Lanchbury, J., Pitzalis, C., Drossaers-Bakker, W. K., Westendorp, R. G., Breedveld, F. C., Panayi, G., Verweij, C. L. (2000) Are differences in interleukin 10 production associated with joint damage? Rheumatology (Oxford) 39, 1180-1188.
16. Clark, K., MacKenzie, K. F., Petkevicius, K., Kristariyanto, Y., Zhang, J., Choi, H. G., Peggie, M., Plater, L., Pedrioli, P. G., McIver, E., Gray, N. S., Arthur, J. S., Cohen, P. (2012) Phosphorylation of CRTC3 by the saltinducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc. Natl. Acad. Sci. USA 109, 16986-16991.
17. Ozanne, J., Prescott, A. R., Clark, K. (2015) The clinically-approved drugs Dasatinib and Bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases. Biochem. J. 465, 271-279.
18. Katoh, Y., Takemori, H., Horike, N., Doi, J., Muraoka, M., Min, L., Okamoto, M. (2004) Salt-inducible kinase (SIK) isoforms: their involvement in steroidogenesis and adipogenesis. Mol. Cell. Endocrinol. 217, 109-112.
19. Clark, K. (2014) Protein kinase networks that limit TLR signalling. Biochem. Soc. Trans. 42, 11-24.
20. Cohen, P. (2014) The TLR and IL-1 signalling network at a glance. J. Cell Sci. 127, 2383-2390.
21. Sundberg, T. B., Choi, H. G., Song, J. H., Russell, C. N., Hussain, M. M., Graham, D. B., Khor, B., Gagnon, J., O’Connell, D. J., Narayan, K., Dančík, V., Perez, J. R., Reinecker, H. C., Gray, N. S., Schreiber, S. L., Xavier, R. J., Shamji, A. F. (2014) Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc. Natl. Acad. Sci. USA 111, 12468-12473.
22. Gabay, C., Lamacchia, C., Palmer, G. (2010) IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 6, 232-241.
23. Dinarello, C. A. (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732.
24. Sironi, M., Martinez, F. O., D’Ambrosio, D., Gattorno, M., Polentarutti, N., Locati, M., Gregorio, A., Iellem, A., Cassatella, M. A., Van Damme, J., Sozzani, S., Martini, A., Sinigaglia, F., Vecchi, A., Mantovani, A. (2006) Differential regulation of chemokine production by Fcgamma receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, type 2). J. Leukoc. Biol. 80, 342-349.
25. Jaguin, M., Houlbert, N., Fardel, O., Lecureur, V. (2013) Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell. Immunol. 281, 51-61.
26. Pfaffl, M. W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45.
27. Livak, K. J., Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(2Delta Delta C(T)) method. Methods 25, 402-408.
28. Hayes, M. P., Wang, J., Norcross, M. A. (1995) Regulation of interleukin-12 expression in human monocytes: selective priming by interferongamma of lipopolysaccharide-inducible p35 and p40 genes. Blood 86, 646-650.
29. Ambarus, C. A., Krausz, S., van Eijk, M., Hamann, J., Radstake, T. R., Reedquist, K. A., Tak, P. P., Baeten, D. L. (2012) Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J. Immunol. Methods 375, 196-206.
30. Mosser, D. M., Edwards, J. P. (2008) Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969.
31. Edwards, J. P., Zhang, X., Frauwirth, K. A., Mosser, D. M. (2006) Biochemical and functional characterization of three activated macrophage populations. J. Leukoc. Biol. 80, 1298-1307.
32. Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., Locati, M. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677-686.
33. Luan, B., Goodarzi, M. O., Phillips, N. G., Guo, X., Chen, Y. D., Yao, J., Allison, M., Rotter, J. I., Shaw, R., Montminy, M. (2014) Leptin-mediated increases in catecholamine signaling reduce adipose tissue inflammation via activation of macrophage HDAC4. Cell Metab. 19, 1058-1065.
34. MacKenzie, K. F., Clark, K., Naqvi, S., McGuire, V. A., Nöehren, G., Kristariyanto, Y., van den Bosch, M., Mudaliar, M., McCarthy, P. C., Pattison, M. J., Pedrioli, P. G., Barton, G. J., Toth, R., Prescott, A., Arthur, J. S. (2013) PGE(2) induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J. Immunol. 190, 565-577.
35. Lizcano, J. M., Göransson, O., Toth, R., Deak, M., Morrice, N. A., Boudeau, J., Hawley, S. A., Udd, L., Mäkelä, T. P., Hardie, D. G., Alessi, D. R. (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 23, 833-843.
36. Alessi, D. R., Sakamoto, K., Bayascas, J. R. (2006) LKB1-dependent signaling pathways. Annu. Rev. Biochem. 75, 137-163.
37. Xie, Z., Dong, Y., Zhang, M., Cui, M. Z., Cohen, R. A., Riek, U., Neumann, D., Schlattner, U., Zou, M. H. (2006) Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-activated protein kinase in cultured endothelial cells. J. Biol. Chem. 281, 6366-6375.
38. Carroll, K. C., Viollet, B., Suttles, J. (2013) AMPKa1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling. J. Leukoc. Biol. 94, 1113-1121.
39. Saraiva, M., O’Garra, A. (2010) The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10, 170-181.
40. Saraiva, M., Christensen, J. R., Tsytsykova, A. V., Goldfeld, A. E., Ley, S. C., Kioussis, D., O’Garra, A. (2005) Identification of a macrophagespecific chromatin signature in the IL-10 locus. J. Immunol. 175, 1041-1046.
41. Yong Kim, S., Jeong, S., Chah, K. H., Jung, E., Baek, K. H., Kim, S. T., Shim, J. H., Chun, E., Lee, K. Y. (2013) Salt-inducible kinases 1 and 3 negatively regulate Toll-like receptor 4-mediated signal. Mol. Endocrinol. 27, 1958-1968.
42. Sanosaka, M., Fujimoto, M., Ohkawara, T., Nagatake, T., Itoh, Y., Kagawa, M., Kumagai, A., Fuchino, H., Kunisawa, J., Naka, T., Takemori, H. (2015) Salt-inducible kinase 3 deficiency exacerbates lipopolysaccharideinduced endotoxin shock accompanied by increased levels of proinflammatory molecules in mice. Immunology 145, 268-278.
43. Chan, E. S., Cronstein, B. N. (2010) Methotrexate—how does it really work? Nat. Rev. Rheumatol. 6, 175-178.
44. Malfait, A. M., Malik, A. S., Marinova-Mutafchieva, L., Butler, D. M., Maini, R. N., Feldmann, M. (1999) The beta2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: mechanisms of action. J. Immunol. 162, 6278-6283.
45. Schafer, P. H., Parton, A., Capone, L., Cedzik, D., Brady, H., Evans, J. F., Man, H. W., Muller, G. W., Stirling, D. I., Chopra, R. (2014) Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell. Signal. 26, 2016-2029.